Mr. Jimmy Whyte, a 64-year-old retiree in Kahnawake, QU, was prescribed Actos to treat his Type 2 diabetes in 2008. In April of this year, he was diagnosed with bladder cancer. Mr. Whyte and his representatives allege that the defendants knew, or should have known, that the diabetes drug increased the risk of bladder cancer after a year.
“It would have been important to know that ACTOS would increase my risks of developing bladder cancer before I began taking it. I believe this class action is necessary to determine whether the manufacturer of this drug should be held responsible for not disclosing such important information to me,” Mr. Whyte stated.
Actos was approved for use in Canada in August 2000. In 2010, a number of complaints against Actos were filed with the FDA, and studies began linking the drug to an increased risk not only of bladder cancer, but also of heart disease. In 2011, both France and Germany removed the drug from their markets, while the FDA issued strong warnings against using the drug. In the United States, Actos has not yet been recalled.
Meanwhile, Takeda Pharmaceuticals has created a new drug called alogliptin, which uses pioglitazone (the generic name for Actos). Their requests for FDA approval have been denied twice, but they recently resubmitted their application with new data.
In the United States, suits against Takeda Pharmaceuticals have been consolidated into one multidistrict litigation (MDL), named MDL 2299. Judge Rebecca Doherty presides over the MDL in the district court of Western Louisiana (Lafayette). She recently extended the deadline to submit claims against the defendants, and released a detailed schedule for the proceedings, including the first bellwether trial in November 2014.
If you or a loved one were prescribed Actos to treat Type 2 diabetes, and have been diagnosed with bladder cancer, heart disease, liver problems, or macular edema, you may be entitled to compensation. The experienced lawyers at Strom Law, LLC, are accepting cases nationwide against Actos and Takeda Pharmaceuticals. Please contact us today for a free consultation. We can help get you on the road to recovery. 803.252.4800.